The FDA has rarely been accused of moving quickly, but the life sciences industry is suddenly acting as if it might.
On Wednesday, February 4, 2026, at the reliably early hour of 8:30 a.m. Pacific (11:30 a.m. Eastern), TRIBE PUBLIC will host a CEO Q&A webinar with Steven A. Ledger, the chief executive of Serina Therapeutics (NYSE: SER). The title, “Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences,” suggests that mere survival will no longer be enough; companies are now expected to have a strategy, a pipeline, and a working understanding of acronyms.
Mr. Ledger will discuss how Serina plans to steer through a regulatory landscape that is becoming more demanding, more data‑driven, and—judging by recent guidance—slightly less tolerant of PowerPoint optimism unaccompanied by clinical results. Investors and industry observers will hear how the company is allocating capital, prioritizing programs, and trying to ensure that “future of life sciences” refers to innovation and not just the longevity of FDA review cycles.
For portfolio managers, analysts, and scientifically inclined insomniacs on the West Coast, the session offers a chance to pose questions directly to a CEO whose job is to translate complex pharmacology into something that can fit into an earnings call. Attendance is free, which may be the only deflationary force currently visible in healthcare.
Registration, unlike drug approval, takes only a few clicks at New-FDA-Era.TribePublic.com.
